Novartis's HARBOR Miss Tests Confidence in the Growth Plan & Rasonque's Access Hurdles

Novartis has another pivotal miss. The setbacks we've followed now raise a bigger question about its growth plan.

And Rasonque's launch shows the work between approval and patients getting treatment. *[Theme sting]*

Welcome to The Pharma Closeout for Tuesday, September eighth. I'm Alex Mercer.

And I'm Maya Patel.

Novartis's del-desiran missed HARBOR's primary endpoint in myotonic dystrophy type one, a disease that progressively weakens muscles. This was a pivotal trial. Patients waiting for a treatment now face an unresolved development path, and Novartis has another expected growth contributor in question.

The primary measure was video hand opening time. Del-desiran did not show a statistically significant improvement over placebo. Novartis reported activity on some secondary and exploratory measures and said safety was generally consistent with earlier studies. But we don't have the numerical package. Those statements don't reverse the primary miss or tell us what happens to the program next.

We've followed this sequence with you. On August thirty-first, we covered Novartis's autoimmune CAR-T pause. On Friday, we led with pelacarsen's cardiovascular miss, then returned to both stories in Sunday's review. Today's result adds a different question: how much of the growth plan now depends on the programs still standing?

That portfolio question is fair. But the autoimmune CAR-T program was paused for safety; pelacarsen and del-desiran missed efficacy endpoints. Three setbacks with different scientific questions. If you downgrade another program, you need a reason tied to that program's evidence. Sharing a company name isn't enough.

Novartis acquired Avidity for twelve billion dollars. Reuters reports that the company is keeping its five-to-six percent compound annual sales-growth outlook from twenty twenty-five through twenty thirty. You can leave another drug's odds unchanged and still become more dependent on it succeeding.

Which assumptions would you revisit first?

The contribution expected from each remaining growth driver, and the evidence behind it. Counting programs won't answer that. A portfolio with several drugs can still depend heavily on one or two delivering. That's the question I'd bring into the next Novartis discussion.

And HARBOR's full results need to explain how large the difference was, how the secondary endpoints were tested, and what the safety data show. A primary miss changes this program's evidence. It doesn't give us a verdict on every drug Novartis bought with Avidity.

On the pipeline side, we can close another loop. Monday's edition previewed Roivant and Pulmovant's PHocus results. Now we have the data for inhaled mosliciguat in pulmonary hypertension associated with interstitial lung disease.

At week sixteen, mosliciguat met the primary endpoint: a placebo-adjusted reduction in pulmonary vascular resistance of fifty-six point three percent. Six-minute walk distance improved by thirty-five point two meters versus placebo. Those results point in the same direction: lower vascular resistance and better function. Cough occurred in about twelve percent on mosliciguat versus eighteen percent on placebo.

Which walking result belongs in the headline?

Week sixteen. The larger walking result came from the exploratory week-twenty-four follow-up. Putting it first would blur the prespecified week-sixteen evidence with the exploratory follow-up.

That gives Monday's preview a useful answer: consistent Phase 2 evidence to support the next test. The longer-term outcome is still ahead.

AstraZeneca's tozorakimab moves us to Phase 3 COPD evidence. In former smokers, moderate or severe exacerbations fell twenty-nine percent in OBERON and thirty-four percent in TITANIA versus placebo. Benefit was also reported in the overall populations, including current smokers. The two trials give us a way to judge whether the effect is consistent, rather than relying on one positive study.

We discussed broad-population benefit in March. Today's advance is the full replicate data and Priority Review, with AstraZeneca anticipating an FDA decision in the first quarter of twenty twenty-seven. For competitors, broad trial enrollment and a broad final label are still separate assumptions. That distinction matters when sizing the opportunity.

Pharvaris reported an eighty-three percent reduction in monthly hereditary angioedema attacks versus placebo with extended-release deucrictibant in the Phase 3 Chapter Three study. Eighty-five people were randomized over twenty-four weeks. The company reported no treatment-related serious adverse events, with one discontinuation in each group.

For Pharvaris, the positioning question is how much attack prevention an oral regimen can deliver with an acceptable treatment burden. This is prophylaxis, distinct from treating an attack once it starts. Comparing it with other prevention options will require more than lining up percentages from different trials.

Amgen and AstraZeneca report a Phase 3 survival win for tarlatamab plus durvalumab in DeLLphi-305. It puts the combination in the first-line maintenance conversation for extensive-stage small-cell lung cancer. Progression-free survival and response-rate endpoints were also met, with no new or unexpected safety signal reported.

This is an earlier-line competitive move, but the magnitude is still missing. We do not have hazard ratios, medians, response rates, or p-values. The endpoint win earns attention; benefit-risk judgment waits for the congress presentation.

Inhibrx's Phase 2 HexAgon study adds a durability result in head-and-neck cancer. Its drug, INBRX one-oh-six, combined with pembrolizumab, had interim median progression-free survival of nine point six months versus four point nine months for pembrolizumab alone.

Does that answer the question we left open in May?

It starts to. May's response-rate update left durability unresolved. Today's interim PFS starts to answer that. The study is small, so the next question is whether that separation persists with longer follow-up.

That's a material follow-up: a different endpoint advancing the same clinical question.

One final clinical marker, in multiple myeloma. Bristol Myers says arlocabtagene autoleucel met the prespecified overall-response and complete-response endpoints in the Phase 2 QUINTESSENTIAL study after prior BCMA-directed therapy. No response rates, durability, or detailed safety results were disclosed.

For arlo-cel, activity after prior BCMA treatment is the relevant development. The response depth, duration and safety will determine how competitive that option could be.

Shifting to the deal side, BrainChild Bio closed a one hundred sixteen million dollar Series A. What clinical test is that money supporting?

BCB two-seven-six's ILLUMINATE study in diffuse intrinsic pontine glioma, a devastating brain cancer, and an earlier glioblastoma program. ILLUMINATE is an open-label, single-arm Phase 2 trial after radiation, with overall survival as its primary endpoint. The sponsor calls it pivotal and says the design reflects FDA alignment. Without a randomized comparator, how the survival evidence is interpreted will matter enormously. The financing supports that work; the results still have to justify the treatment.

Sernova and Seraxis propose a roughly fifty-fifty merger to create BetaNova. The plan combines Sernova's Cell Pouch device with Seraxis's islet-cell program and manufacturing capabilities for type one diabetes. Ten million dollars in convertible-note commitments would support development; those commitments aren't a valuation. I can see the integration argument: put cell supply, implantation and manufacturing under one roof to help coordination. Clinical proof of the combined approach is a separate challenge.

And it remains ahead. The companies still expect the merger to close in November, so the proposed integration itself is also unfinished.

On the regulatory side, Intellia says the FDA accepted its application for lonvo-z, the gene-editing therapy for hereditary angioedema, and granted Priority Review. The company reports a March tenth, twenty twenty-seven action date.

We covered the Phase 3 result in April. Today's change is an accepted review with a date teams can plan around. It also puts another approach to HAE prevention on the regulatory calendar alongside the Pharvaris data we discussed. Different development stages, and no head-to-head evidence to rank them.

Quick note before our second story — if The Pharma Closeout is how you close out your day, follow the show on Spotify or Apple Podcasts. Revolution Medicines' pancreatic cancer drug Rasonque brings us to the work after approval: getting treatment into patients' hands.

STAT reported two patients who encountered access barriers after approval. Both cases reached a resolution by publication. One involved an initial OptumRx denial followed by prior-authorization approval. In the other, a family reported sixty-one calls in forty-eight hours while trying to obtain treatment.

Revolution then provided that family a thirty-day supply, and Aetna told them it would cover Rasonque for a year. The resolution matters. So does the work the family had to do to reach it.

Revolution has published Quick Start and Bridge support for qualifying insurance delays. Eligibility has conditions. These cases don't establish a general payer denial policy or tell us how often the transition fails.

For a launch update, ask where a patient is waiting: authorization, support enrollment, or dispensing. A coverage decision alone won't tell you whether treatment actually reached them.

That's the follow-through to watch: whether the next patient can navigate those handoffs without the same escalation. Approval is a milestone. Reliable access has to be demonstrated in practice.

Enjoy your evening.

That's your Pharma Closeout for Tuesday: Novartis's growth assumptions, PHocus's new data, and Rasonque's access handoffs. Follow the show on Apple Podcasts, Spotify, or wherever you listen — a quick rating or share helps other listeners find us. Tomorrow's briefing lands on its own. ## Sources and evidence boundaries All11stories source-cleared with claim-specific attribution and limits. See stage5-claim-source-ledger.json and stage5-source-clearance.md. Rap-cel callback rests on the August31 aired record and its trade sources, not a fetched company disclosure. Barron’s subscriber body is not used. ### SEP08-NOVARTIS-HARBOR - https://www.novartis.com/us-en/news/media-releases/novartis-provides-update-delpacibart-etedesiran-del-desiran-phase-iii-harbor-study-treatment-myotonic-dystrophy-type-1-dm1 - https://clinicaltrials.gov/study/NCT06411288 - https://www.investing.com/news/stock-market-news/novartis-twin-drug-setbacks-pile-pressure-on-pipeline-and-ceo-4891414 - https://www.biopharmadive.com/news/autoimmune-cell-therapy-safety-novartis-bristol-kyverna-cabaletta/829413/ - https://www.novartis.com/news/media-releases/novartis-announces-lpahorizon-phase-iii-topline-results-pelacarsen-patients-elevated-lpa-and-established-cardiovascular-disease-cvd ### C001 - https://investor.roivant.com/news-releases/news-release-details/roivant-announces-positive-results-phocus-study-mosliciguat - https://www.sec.gov/Archives/edgar/data/1635088/000114036126035859/ef20081686_ex99-1.htm ### C002 - https://pubmed.ncbi.nlm.nih.gov/42708515/ - https://www.astrazeneca.com/media-centre/press-releases/2026/tozorakimab-demonstrated-statistically-significant-highly-clinically-meaningful-reduction-copd-exacerbations-oberon-titania-phase-iii-trials.html ### C004 - https://www.sec.gov/Archives/edgar/data/1830487/000119312526384339/phvs-ex99_1.htm ### C003 - https://www.sec.gov/Archives/edgar/data/901832/000165495426008172/a8764t.htm - https://amgen.gcs-web.com/news-releases/news-release-details/imdelltrar-combination-imfinzir-demonstrated-landmark - https://clinicaltrials.gov/study/NCT06211036 ### C005 - https://inhibrx.investorroom.com/2026-09-08-Inhibrxs-INBRX-106-Nearly-Doubles-Response-Rate-and-Achieves-Interim-Median-PFS-of-9-6-months-in-Phase-2-HNSCC-Study ### C006 - https://news.bms.com/news/corporate-financial/2026/Bristol-Myers-Squibb-Announces-Positive-Topline-Results-from-Registrational-Phase-2-QUINTESSENTIAL-Trial-of-the-Potential-First-in-Class-GPRC5D-Directed-CAR-T-Cell-Therapy-Arlocabtagene-Autoleucel----/default.aspx - https://clinicaltrials.gov/study/NCT06297226 ### D010 - https://brainchildbio.com/wp-content/uploads/2026/09/BCBio_SeriesA_PR_FINAL_09-08-26.pdf - https://clinicaltrials.gov/study/NCT07680439 - https://brainchildbio.com/wp-content/uploads/2026/09/BCBio_Phase2InitiationPR_FINAL_09-08-26.pdf ### D008 - https://sernova.com/press_releases/sernova-and-seraxis-enter-definitive-merger-agreement-to-create-a-differentiated-type-1-diabetes-islet-cell-replacement-biotech-company-betanova-biotherapeutics/ - https://www.bioxconomy.com/partnering/betanova-biotherapeutics-emerges-from-sernova-seraxis-merger - https://clinicaltrials.gov/study/NCT07581197 ### D006 - https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-fda-acceptance-biologics-license ### ROOT-01 - https://www.statnews.com/2026/09/08/pancreatic-cancer-patients-caught-beween-fda-drug-approval-insurance-coverage/ - https://hcp.revmedonpath.com/financial-resources - https://clinicaltrials.gov/study/NCT07573215